Journal
JOURNAL OF CLINICAL MEDICINE
Volume 10, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/jcm10040853
Keywords
inflammatory bowel disease; biological therapy; predictors; biomarkers
Categories
Ask authors/readers for more resources
Inflammatory bowel diseases are chronic conditions that affect the gastrointestinal tract, with a significant clinical heterogeneity. Despite an expanding pipeline of therapies, there is currently no ideal marker to predict patient response, but multiparametric models show promise in this regard.
Inflammatory bowel diseases (IBD) are chronic conditions that primarily affect the gastrointestinal tract, with a complex pathogenesis; they are characterized by a significant heterogeneity of clinical presentations and of inflammatory pathways that sustain intestinal damage. After the introduction of the first biological therapies, the pipeline of therapies for IBD has been constantly expanding, and a significant number of new molecules is expected in the next few years. Evidence from clinical trials and real-life experiences has taught us that up to 40% of patients do not respond to a specific drug. Unfortunately, to date, clinicians lack a valid tool that can predict each patient's response to therapies and that could help them in choosing what drug to administer. Several candidate biomarkers have been investigated so far, with conflicting results: clinical, genetic, immunological, pharmacokinetic and microbial markers have been tested, but no ideal marker has been identified so far. Based on recent evidence, multiparametric models seemingly hold the greatest potential for predicting response to therapy. In this narrative review, we aim to summarize the current knowledge on predictors and early markers of response to biological therapies in IBD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available